# Innovent Biologics Innovent Biologics is an Asset Manager based in Suzhou, China. ## Overview - **Organization type:** Asset Manager - **Headquarters:** Suzhou, China - **Region:** Asia - **Address:** Suzhou, Jiangsu, China - **Founded:** 2011 - **Assets under management:** Undisclosed - **Website:** innoventbio.com ## Regulatory record - **Reports private funds:** No ## About Innovent Biologics was established in 2011 by Dr. Michael Yu, a former VP at Eli Lilly with deep R&D experience, alongside a core team of scientists. The company was built to develop and commercialize high-quality biologics for the Chinese and global markets. It rapidly scaled by leveraging partnerships with global pharma, most notably a 2015 licensing deal with Eli Lilly and later a 2021 strategic collaboration on sintilimab, positioning itself as the bridge between Western drug innovation and Asian market access. The firm's strategy centers on an integrated discovery-through-commercialization platform. Its portfolio is anchored by sintilimab, a PD-1 inhibitor approved in China for multiple cancer indications and under review internationally. Beyond immuno-oncology, Innovent pushes into the next wave: a Co-STAR T cell engager platform, bispecific antibodies targeting CLDN18.2 and CD47, and an ophthalmology asset licensed from AnHeart Therapeutics. Its manufacturing footprint in Suzhou covers monoclonal antibodies and cell therapy, fueling clinical trials spanning 10 countries from China and South Korea to the United States and Australia. Innovent employs over 5,000 professionals across offices in Suzhou, Shanghai, and San Francisco. The company maintains no external fund structure — all capital deployment is directed toward internal R&D, manufacturing scale-up, and commercial infrastructure. A 2022 deal with Sanofi involving two oncology assets provided an equity infusion and deep clinical development support, signaling a shift toward major pharma co-development rather than pure licensing. Most recently, the firm advanced its CLDN18.2 bispecific antibody into a Phase 3 global trial in gastric cancer, cementing its late-stage pipeline heft. Its structural differentiator lies in owning the entire biologics value chain — from antibody discovery using its proprietary yeast display library to large-scale commercial manufacturing in China — a model that allows rapid speed-to-market for biosimilars while internally funding the high-risk, high-reward bispecific and cell therapy programs. This vertically integrated architecture is rare among Chinese biotechs, which typically function as asset-discovery shops outsourcing manufacturing or rely heavily on out-licensing to survive. ## Sectors - Biotechnology - Healthcare Services ## Offices - Shanghai, China - San Francisco, CA, United States ## People - Michael Yu — Founder, Chairman, and CEO - Scott Filosi — Chief Business Officer ## Questions ### How does Innovent source its drug candidates? Innovent uses a hybrid model. Many early-stage assets originate from its proprietary yeast display-based antibody discovery platform. The firm also in-licenses mid-stage assets from global biotechs — a 2021 ophthalmology deal with AnHeart Therapeutics and a 2022 oncology collaboration with Sanofi are notable examples. This reduces reliance on any single discovery method and spreads clinical risk. ### Who makes the final investment decisions on which drug programs to pursue? Dr. Michael Yu, the founder and CEO, sets the strategic portfolio direction. The Scientific Advisory Board, which includes external oncology and immunology experts, reviews pipeline candidates. A portfolio governance committee consisting of the CSO, CMO, and Chief Business Officer formally prioritizes programs based on clinical data and commercial potential per the firm's public filings. ### Does Innovent have any co-investment vehicles for external LPs? No. Innovent does not operate or sponsor any investment funds for outside limited partners. All R&D is funded through revenue, public equity, and strategic pharma partnerships. External allocators gain exposure only by purchasing Innovent shares on the Hong Kong Stock Exchange. ### What differentiates Innovent from other Chinese biotech firms listed in Hong Kong? Innovent owns in-house, large-scale commercial manufacturing for monoclonal antibodies — a capability that rival asset-discovery firms like CStone or Zai Lab generally outsource. Its Suzhou facility also handles its cell therapy production. This vertical integration gives Innovent control over cost, speed, and biosimilar market entry, a structural advantage that purely clinical-stage peers lack. ### Which sectors or therapeutic areas does the firm explicitly avoid? Innovent has publicly avoided CNS and rare disease indications. Its pipeline is heavily concentrated in oncology, autoimmune, and metabolic diseases where large patient populations make the economics of its high-volume manufacturing model viable. It has shown no interest in antibiotics or antivirals outside of pandemic-response research. ## Related profiles - [Lasertec Corporation](https://altss.com/profile/lasertec-corporationadr) - [Lord Abbett Credit Opportunities Fund](https://altss.com/profile/lord-abbett-credit-opportunities-fund) --- Last updated: 2026-06-03T20:00:00.000Z Canonical page: https://altss.com/profile/innovent-biologics-incadr Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology